Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lyell Immunopharma (LYEL) Gains from Investment Securities: 2020-2024

Historic Gains from Investment Securities for Lyell Immunopharma (LYEL) over the last 1 years, with Mar 2024 value amounting to $13.0 million.

  • Lyell Immunopharma's Gains from Investment Securities rose 30.01% to $13.0 million in Q1 2024 from the same period last year, while for Mar 2024 it was $30.9 million, marking a year-over-year decrease of 39.63%. This contributed to the annual value of $13.0 million for FY2024, which is 0.60% up from last year.
  • Latest data reveals that Lyell Immunopharma reported Gains from Investment Securities of $13.0 million as of Q1 2024, which was up 344.78% from $2.9 million recorded in Q2 2023.
  • Lyell Immunopharma's Gains from Investment Securities' 5-year high stood at $36.2 million during Q4 2021, with a 5-year trough of -$28,000 in Q1 2022.
  • In the last 3 years, Lyell Immunopharma's Gains from Investment Securities had a median value of $5.0 million in 2022 and averaged $6.2 million.
  • In the last 5 years, Lyell Immunopharma's Gains from Investment Securities tumbled by 165.12% in 2022 and then soared by 35,814.29% in 2023.
  • Quarterly analysis of 5 years shows Lyell Immunopharma's Gains from Investment Securities stood at $7.0 million in 2020, then spiked by 417.75% to $36.2 million in 2021, then skyrocketed by 11,804.76% to $5.0 million in 2022, then skyrocketed by 35,814.29% to $2.9 million in 2023, then skyrocketed by 30.01% to $13.0 million in 2024.
  • Its Gains from Investment Securities was $13.0 million in Q1 2024, compared to $2.9 million in Q2 2023 and $10.0 million in Q1 2023.